News and Updates

A new Breakthrough T1D-funded study finds that people with T1D and their caregivers are largely willing to try advanced new T1D therapies.

Breakthrough T1D’s newest publication outlines a roadmap for beta cell replacement therapies for type 1 diabetes.

Hypoimmune (HIP) islets are making insulin, without immunosuppressants, in the first person treated with type 1 diabetes.

Breakthrough T1D was in Chicago, IL for ADA 2025. Here we report on the latest advancements in cures for type 1 diabetes.

Improving Lives Breakthrough T1D’s Improving Lives program focuses on devices, insulins, adjunctive therapies, treatments for complications, and psychosocial interventions to improve the health and quality of life of people living with T1D. Adjunctive therapies and complications There was significant focus on GLP-1 receptor agonists (GLP-1RAs) and SGLT inhibitors (SGLTi) in reducing long-term complications and improving […]

This Clinical Trials Awareness Day, we’re exploring lessons from clinical trials and debunking clinical trials misconceptions.

Breakthrough T1D believes that novel cell therapies in the clinical pipeline will transform T1D management, and Project ACT is how we’re going to make them a reality.

Learn more about GLP-1 therapies and SGLT inhibitors, and how drugs like Ozempic may one day be able to help people with type 1 diabetes.

Katie Howell was diagnosed with type 1 diabetes last year at age 25. Now, she's the first DIAGNODE-3 trial participant in NYC.

Breakthrough T1D's new Medical Affairs unit will address the numerous challenges contributing to the slow adoption of groundbreaking T1D therapies.